These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37909622)

  • 41. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
    Kalampokas T; Creatsas G; Kalampokas E
    Gynecol Endocrinol; 2013 Feb; 29(2):98-100. PubMed ID: 23110560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome.
    Hosseini MA; Aleyasin A; Mahdavi A; Nezami R; Safdarian L; Fallahi P
    Iran J Med Sci; 2011 Sep; 36(3):207-12. PubMed ID: 23359545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
    Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
    Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sphingosine-1-phosphate restores endothelial barrier integrity in ovarian hyperstimulation syndrome.
    Scotti L; Di Pietro M; Pascuali N; Irusta G; I de Zúñiga ; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2016 Dec; 22(12):852-866. PubMed ID: 27645281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS).
    Birinci H; Vatansever HS; Yüncü M
    Reprod Fertil Dev; 2021 Nov; 33(16):799-809. PubMed ID: 34610858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
    Kitsou C; Kosmas I; Lazaros L; Tzallas C; Tinelli A; Mynbaev O; Prapas N; Prapas I; Dalkalitsis A; Georgiou I
    Gynecol Endocrinol; 2016 Nov; 32(11):886-890. PubMed ID: 27223459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study.
    Turan GA; Eskicioglu F; Sivrikoz ON; Cengiz H; Adakan S; Gur EB; Tatar S; Sahin N; Yilmaz O
    Arch Gynecol Obstet; 2015 Nov; 292(5):1163-71. PubMed ID: 25990477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication.
    Ohba T; Ujioka T; Ishikawa K; Tanaka N; Okamura H
    Mol Cell Endocrinol; 2003 Apr; 202(1-2):47-52. PubMed ID: 12770729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B; Aboulghar M; Smitz J; Ron-El R
    Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.
    Kılıç N; Özdemir Ö; Başar HC; Demircan F; Ekmez F; Yücel O
    Avicenna J Med; 2015; 5(4):123-7. PubMed ID: 26629467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful reversal of ovarian hyperstimulation syndrome in a mouse model by rapamycin, an mTOR pathway inhibitor.
    Liu W; Zhang C; Wang L; Huang X; Zhang J; He Y; Chen L; Li J
    Mol Hum Reprod; 2019 Aug; 25(8):445-457. PubMed ID: 31329230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.
    Chuderland D; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Ron-El R; Shalgi R
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E258-66. PubMed ID: 23295464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High dose cabergoline in management of ovarian hyperstimulation syndrome.
    Ata B; Seyhan A; Orhaner S; Urman B
    Fertil Steril; 2009 Sep; 92(3):1168.e1-1168.e4. PubMed ID: 19539908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.
    Bishop CV; Lee DM; Slayden OD; Li X
    J Ovarian Res; 2017 Jul; 10(1):41. PubMed ID: 28683759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of intravenous calcium gluconate on the prevention of ovarian hyperstimulation syndrome. (A randomized clinical trial).
    Lotfalizadeh M; Khadem N; Sadeghi T; Jahanpak N; Mahmoudinia M; Faraji P; Zakerinasab F; Mahmoudinia M
    J Gynecol Obstet Hum Reprod; 2024 Dec; 53(10):102850. PubMed ID: 39293587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor.
    Tahermanesh K; Hakimpour S; Govahi A; Keyhanfar F; Kashi AM; Chaichian S; Shahriyaripour R; Ajdary M
    Biomed Res Int; 2022; 2022():1111777. PubMed ID: 36588534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
    Soares SR; Gómez R; Simón C; García-Velasco JA; Pellicer A
    Hum Reprod Update; 2008; 14(4):321-33. PubMed ID: 18385260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS.
    Inal HA; Ozturk Inal ZH; Yilmaz N; Timur H; Oruc AS; Kalem MN; Han O
    Clin Exp Obstet Gynecol; 2017; 44(1):122-128. PubMed ID: 29714880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
    Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
    Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Betaine Attenuates The Expression of Vasoactive Mediators and Histological Alterations Associated with Ovarian Hyperstimulation Syndrome in Rats.
    Abbasi MR; Jamshidian J; Basir Z; Tabandeh MR
    Cell J; 2024 May; 26(4):259-266. PubMed ID: 38736410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.